Instituto Nacional de Cancerología

Their core work

Instituto Nacional de Cancerología (INCan) is Mexico's national cancer reference centre, combining clinical oncology care with translational research. In the H2020 context, they function as a bridge institution — providing access to Latin American patient cohorts, clinical data, and diagnostic expertise that European consortia cannot replicate internally. Their documented work spans rare mesenchymal tumors (sarcoma) and upper gastrointestinal cancers (gastric cancer), with a methodological focus on improving diagnosis, clinical care pathways, and applying omics-based approaches to personalised treatment. As a national reference centre, they hold the institutional authority to translate research findings directly into clinical protocols.

What they specialise in

How they've shifted over time

Both H2020 projects launched in 2019, so this is topic breadth rather than true temporal evolution — caution is warranted. That said, the thematic arc is readable: SELNET grounds INCan in rare tumor diagnostics and clinical care, while LEGACy extends toward data-intensive methods (omics, integrative epidemiology) applied to a high-incidence cancer type in their region. The shift from morphological diagnosis to molecular profiling and personalised treatment reflects a trajectory consistent with the broader oncology field. If INCan follows this direction, future projects are likely to involve multi-omics platforms, biomarker discovery, and AI-assisted cancer diagnostics.

INCan appears to be moving from clinical-descriptive rare tumor research toward data-intensive precision oncology, making them a plausible partner for future biomarker, multi-omics, or AI-in-oncology projects with a Latin American dimension.

How they like to work

INCan has participated in H2020 exclusively as a consortium member, never as coordinator — consistent with their role as a clinical anchor institution rather than a project management hub. Both projects were large, transcontinental consortia (EU + Latin America / CELAC), suggesting INCan is valued specifically for their geographic and clinical positioning rather than their research infrastructure scale. With 21 distinct partners across 13 countries from only 2 projects, they engage in broad, multi-institutional networks rather than tight bilateral partnerships.

Despite only two projects, INCan has connected with 21 partners in 13 countries — an unusually broad footprint that reflects the transcontinental character of both SELNET and LEGACy, which explicitly bridge European and Latin American research systems. Their network is genuinely global, not European-centric.

What sets them apart

INCan's core differentiation is access: as Mexico's national cancer reference centre, they provide what no European institution can — a clinical gateway into Latin American patient populations, epidemiological data, and healthcare systems. Both H2020 projects were explicitly designed around EU-LatAm scientific cooperation, and INCan's membership was structurally necessary to that design. For any consortium targeting cancers with elevated Latin American incidence (gastric, cervical, sarcoma subtypes) or seeking equity in clinical trial representation, INCan is not a nice-to-have — they are the enabling partner.

Highlights from their portfolio

• SELNET
  A rare-disease model project using sarcoma to develop transferable diagnostic and care improvements across all rare tumor types — notable for its EU-LatAm design and INCan's role as the Latin American clinical anchor.
• LEGACy
  Addresses gastric cancer — a disease with strikingly different incidence rates across Europe and Latin America — through a personalised medicine and omics framework, making cross-population data comparison a core scientific asset.